摘要
该研究对真实世界丹参川芎嗪注射液治疗的缺血性脑血管病联合用药情况进行分析,运用禁忌搜索算法分析缺血性脑血管病药物治疗中的核心药物联合丹参川芎嗪注射液的分布规律,为探索临床核心用药方案提供参考。根据缺血性脑血管病不同类型及病理阶段,筛选组合出适于缺血性脑血管病改善脑循环治疗方案:适于抗血小板治疗的乙酰水杨酸(阿司匹林)+硫酸氢氯吡格雷组合方案;其他改善脑循环治疗的丹参川芎嗪注射液+长春西汀/马来酸桂哌齐特/前列地尔/盐酸倍他司汀组合方案。以脑蛋白水解物+单唾液酸四己糖神经节苷脂+依达拉奉注射液为药物组成的神经修复治疗方案;及以甘露醇注射液/呋塞米/甘油果糖氯化钠注射液+醒脑静注射液+胞磷胆碱为核心药物组成的针对并发脑水肿及意识障碍的治疗方案。研究归纳的用药方案仅供临床医师参考,进一步研究可在该研究基础上,开展前瞻性安全性、有效性评价。
In this study, the real world situation of the combination of Danshen and Ligustrazine Injection in the treatment of ischemic cerebrovascular disease was analyzed. The distribution law of the application of core drug combined with Danshen and Ligustrazine Injection in the treatment of ischemic cerebrovascular disease was studied by using Tabu search algorithm, the reference was provided for the exploration of clinical core drug scheme. According to different types and pathological stages of ischemic cerebrovascular disease, the treatment plan for improving cerebral circulation of ischemic cerebrovascular disease was selected and combined: acetylsalicylic acid(aspirin) + clopidogrel bisulfate combination plan for antiplatelet treatment;Danshen Ligustrazine Injection + vinpocetine/cinepazide maleate/alprostadil/betahistine hydrochloride combination plan for improving cerebral circulation Combination scheme. The treatment plan of nerve repair is composed of cerebroprotein hydrolysate + monosialotetrahexosylganglioside + edaravone injection, and the treatment plan of brain edema and consciousness disorder is composed of mannitol injection/furosemide/glycerin fructose sodium chloride injection + Xingnaojing injection + citicoline. Based on this study, the prospective clinical safety and efficacy evaluation can be carried out for a certain seed group module.
作者
耿洪娇
谢雁鸣
杨云云
Geng Hongjiao;Xie Yanming;Yang Yunyun(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;School of Statistics,Renmin University of China,Beijing 100872,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第3期827-833,共7页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家科学技术部重点研发计划(2018YFC1707410):十种中成药大品种和经典名方上市后治疗重大疾病的循证评价及其效应机制的示范研究,负责人:谢雁鸣。